Background: There is a need for markers that can specifically identify individuals at increased risk of harboring aggressive forms of prostate cancer (PCa). Methods: We surveyed the Kallikrein (KLK) region (KLK1-15) for single-nucleotide polymorphisms (SNPs) associated with aggressive PCa (Gleason Score ! 8) in 1858 PCa patients. Discovery cohorts (Swiss arm of the European Randomized Study of Screening for PCa, n ¼ 379; Toronto, Canada, n ¼ 540) and a validation cohort (Prostate, Lung, Colorectal and Ovarian [PLCO] screening trial, n ¼ 939) were analyzed. Fine-mapping within the KLK region was carried out by genotyping and imputation in the discovery cohort, whereas PLCO data were provided through database of Genotypes and Phenotypes (dbGaP). The influence of SNPs of interest on biochemical-free survival was evaluated in a cohort of localized PCa from the International Cancer Genome Consortium (ICGC; n ¼ 130) analyzed with next-generation sequencing. Single-and multi-SNP association studies, as well as haplotype analyses, were performed. All statistical tests were two-sided. Results: Several SNPs in very strong linkage disequilibrium in the KLK6 region and located within the same haplotype (rs113640578, rs79324425, rs11666929, rs28384475, rs3810287), identified individuals at increased risk of aggressive PCa in both discovery (odds ratio [OR] ¼ 3.51-3.64, 95% confidence interval [CI] ¼ 2.01 to 6.36, P ¼ 1.0x10 À5 -8.4x10 À6 ) and
Prostate Cancer (PCa) is a major health problem and is extremely prevalent in men over the age of 50 years, but its clinical and molecular heterogeneity is such that most men die with rather than from it (1-3). Serum prostate-specific antigen (PSA) screening has led to PCa detection at an earlier, more curable stage. Its perverse effects have included the diagnosis of a considerable proportion of indolent cancers unlikely to progress to a clinically significant, lethal disease. There is an ongoing controversy surrounding PSA screening (4) . Reduced quality of life resulting from overtreatment of indolent tumors has been a problem for many men (5) . Given the limitations of serum PSA as a marker, a major concern is that too many men are subjected to biopsies and often treatment in order to prevent one death from PCa. There is therefore an urgent need for markers that specifically identify men at increased risk of harboring an aggressive form of the disease.
PSA (KLK3) is a member of the kallikrein (KLK) family, which consists of 15 genes (KLK1-15) clustered on chromosome 19q13.4. Several KLKs play major roles in PCa, in particular KLK2 and KLK3 (6) , and have been studied as PCa biomarkers, alone or in combination. In the prospective randomized trial Prostate Testing for Cancer and Treatment (PROTECT), a four kallikrein serum marker panel (free, intact, and total PSA, as well as KLK 2) enhanced not only PCa detection but aggressive high-grade disease in particular, compared with PSA and age alone (7) .
With advances allowing for the identification of germline genetic variants that increase a man's risk for PCa, a growing number of SNPs (now >100) have been identified through genome-wide association studies (GWAS) (8) . However, these are mostly common low-penetrance susceptibility alleles associated with a modest increased risk (8) . With the exception of KLK3, the influence of other KLK gene variants on aggressive PCa remains unclear (9) (10) (11) . SNPs in KLK3, the two intergenic regions KLK15-KLK3 and KLK3-KLK2, and the genes KLK12, KLK13, KLK1, and KLK15 have been associated with PCa aggressiveness (9) (10) 12, 13) and overall survival (14) . Given the established role of the KLK family in PCa, we performed here a fine-mapping study of the entire KLK region, aiming to analyze whether germline polymorphisms in this region were associated with an increased risk of aggressive PCa.
Methods

Study Subjects
In the discovery analysis, two separate cohorts (Table 1) were studied in a case-only design where the distribution of the KLK gene variants was compared between case patients with aggressive PCa (Gleason Score [GS] ! 8) vs. case patients with less aggressive PCa (GS 7) . The use of a case-control design would have led to contamination in the control group by a substantial percentage of latent PCa (3) . The Toronto cohort comprised 540 biopsy-proven PCa case patients (42 with GS ! 8) randomly selected among case patients accrued in the setting of the University Health Network (UHN) Genitourinary (GU) Biobank. The mean PSA for this group was 7.1 ng/mL, with a standard deviation of 8.1 (Table 1) . Clinical data, lymphocyte DNA, serum, and pathology were obtained from Princess Margaret Cancer Centre, UHN, Toronto GU Biobank (Supplementary Methods, available online).
The Swiss cohort is part of the Swiss arm of the European Randomized Study of Screening for PCa (ERSPC) and contains 379 PCa cases (25 with GS ! 8) detected longitudinally over a time span of minimum eight years with three rounds of screening, minimizing the risk of "missing" cancers, which can occur with cross-sectional studies (Supplementary Methods, available online). Controls without PCa were used to infer haplotype blocks. Three hundred eight patients without biopsy-proven PCa from Toronto and 506 patients from the Swiss cohort were used as controls (Supplementary Methods, available online). All patients and controls in the study, both in Toronto and Switzerland, were of Caucasian descent. Patients in Toronto were contacted individually to confirm after research ethics board (REB) approval (REB#: 08-0124-T revised).
As a validation cohort (Table 1) , we used the PCa data from the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial, which includes 15% non-Caucasian men (15) . This data set was chosen for validation because it included approximately the same number of PCa cases (n ¼ 939 including 68 with GS ! 8) (Table 1) as the combined Swiss and Toronto data sets (n ¼ 919 including 67 with GS ! 8). The GWAS genotype data was downloaded from Cancer Genetic Markers of Susceptibility (CGEMS) study in the database of Genotypes and Phenotypes (dbGaP) (accession number phs000207.v1.p1) (16) . SNPs were extracted from the KLK region. Additional SNPs were imputed from the 1000 genomes data. To replicate the Swiss screening data, interval cancers were not included (n ¼ 197).
SNP Calling, Methodology, and Genotyping
Using the existing linkage disequilibrium (LD) data from the Caucasian population available in the HapMap database (17), we systematically retrieved all the tag SNPs with at least 5% minor allele frequency. SNP selection was based on R 2 ¼ 0. 
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All enzyme-linked immunosorbent assay (ELISA) assays were performed using a monoclonal-monoclonal antibody configuration, detailed in the Supplementary Methods (available online) (20) .
Tissue DNA Methylation Methodology
We used a Taqman-based technique that assesses percent DNA methylation by percentage of methylated reference (PMR) at a defined gene locus (21) (22) . We analyzed a cohort of radical prostatectomy patients from the Toronto, Canada, with matched germline DNA. Among this cohort, there were 115 pairs of PCa and normal tissue samples with SNP genotype information and GS available for the PCa specimens. A PMR score was calculated for the KLK6 gene locus by dividing the KLK6 gene:Alu-C4 ratio of a sample by the KLK6 gene:Alu-C4 ratio of commercially available fully methylated DNA (Millipore) and multiplying by 100.
Statistical Analyses
Hardy-Weinberg equilibrium tests were used. The SNPs for which the null hypothesis of Hardy-Weinberg equilibrium was rejected at the Bonferroni statistical significance level were excluded. We performed single SNP associations with the software Plink (23) using Pearson's chi-square statistics and Wald tests for the SNP-specific regression coefficient estimated from logistic model (for aggressive PCa defined as GS ! 7 and GS ! 8) and linear regression (tGS, continuous GS). A covariance analysis was performed on methylation data and KLK6 serum protein levels. Nomograms were constructed to assess predictive values of the statistically significant SNPs in addition to clinical variables (Supplementary Methods, available online).
Haplotype blocks were defined with the software Haploview (24) , where confidence bounds were based on D' values. Haplotype analyses were performed using generalized linear model (GLM) as implemented in the haplo.stats R package (25) . The test of each individual haplotype was based on the Wald statistic for the haplotype-specific GLM regression coefficient, and the test for the overall haplotype effect at a particular locus was based on the likelihood ratio test. The SNPs were also tested against the protein and methylation levels using linear regressions (Supplementary Methods, available online). All other statistical methods are detailed in the Supplementary Methods (available online). All statistical tests were two-sided and used a Bonferroni-adjusted statistical significance threshold of 2.3x10 À4 (i.e. 0.05/220) (see Supplementary Methods).
Germline-Somatic Mutation Analysis
To test for germline-somatic interactions, we compared recurrence rates for a set of common somatic genomic events between patients with the reference or alternate alleles for each SNP. This was done in a cohort of 186 patients, each of whom had whole-genome sequencing of both the tumor and normal (blood) genomes from frozen specimens analyzed as part of the Canadian Prostate Cancer Genome Network (CPC-GENE). This cohort is described in detail elsewhere (26); all data from it is publicly available (https://www.ebi.ac.uk/ega/studies/ EGAS00001000900) and in the International Cancer Genome Consortium (ICGC) data coordinating center (Supplementary  Methods and Supplementary Table 1 , available online).
Association of SNPs With Patient Outcome
Within this 186-patient cohort, survival information was available for 130 patients, enabling evaluation of associations between genotype of the KLK6 SNPs and biochemical relapse (as a proxy for PCa-specific survival) (Supplementary Table 1 , available online). Biochemical recurrence was defined as a PSA rise greater than or equal to 2 ng/mL above post-treatment nadir PSA (ie, Phoenix definition), or triggered salvage treatment for patients treated by radiotherapy (n ¼ 43). For patients treated by radical prostatectomy (n ¼ 87), two consecutive measurements greater than 0.2 ng/mL or that triggered salvage hormone therapy were considered biochemical recurrence. Two Cox proportional hazard regression models were fit. To assess the prognostic impact of the SNPs near KLK6 in the context of the current clinical setting, the models were adjusted for diagnostic GS (6 vs 7-8), pretreatment PSA (continuous), and clinical T group (T1 vs T2). The prognostic impact for each SNP group was visualized in Kaplan-Meier curves implemented using the R packages lattice (v. 0.20-31) and latticeExtra (v. 0.6-26) (27) .
Results
Five noncoding SNPs in the 3.2 kbp KLK6 locus were strongly associated with PCa aggressiveness (GS ! 8 vs GS < 8) in the Swiss cohort (odds ratio [OR] ¼ 5.86, 95% CI ¼ 2.39 to 14.36, Table 2) : rs113640578, rs79324425, rs11666929, rs28384475, and rs3810287. These SNPs were in very strong LD with one another (pairwise D' ¼ 1 and R 2 ! ¼ 0.95, based on 1000 genomes data) and had minor allele frequencies ranging from 6.0% to 8.2% in the 1000 genomes data ) ( Figure 1A and Table 2 ). These SNPs are over-represented in aggressive disease, with 31.3% (21/67) of patients with tumors with GSs of 8 or higher carrying at least one susceptibility allele, compared with only 11.1% (95/852) of patients with tumors with GSs of 7 or less (P ¼ (Supplementary Figure 1, available online) .
We plotted the overall SNP genotype distributions using the multidimensional scaling approach (MDS) and did not detect any subpopulation or outlier observations (Supplementary Figure 2, and D' ! 0.95) with our initial five KLK6 SNPs: rs78353057 and rs201147694 (an indel polymorphism of TTC trinucleotides). Figure 1B shows the relative position of the seven SNPs. Both rs3810287 and rs201147694 are located near the 5'end of the KLK6 gene, while the remaining SNPs are intronic. Supplementary Figure 3 (available online) shows an LD map of the haplotype block. We validated the association between these KLK6 SNPs (rs113640578, rs79324425, rs11666929, rs28384475, and rs3810287) with GS ! 8 in the PLCO data set at the 5% level (OR ¼ 1.89-1.96, 95% CI ¼ 0.99 to 3.71, P ¼ .04-.05) ( Table 3 ). In addition, we found two other KLK6 SNPs associated with PCa aggressiveness in PLCO: rs28665094 (P ¼ .006) and rs268890 (P ¼ .005). These two SNPs are located on a different haplotype than the original five SNPs. When combining the three data sets, six of seven KLK6 SNPs reached very high statistical significance (P ¼ 3.8x10
). Haplotype analysis of the KLK6 locus using the seven SNPs (rs113640578, rs79324425, rs11666929, rs28384475, rs3810287, rs28665094, and rs268890) is shown in ). The overall test of haplotype association (considering the three haplotypes jointly) was very statistically significant in the discovery cohort (P ¼ 3.5x10 À4 ), validation cohort (P ¼ .006), and in the three data sets combined (P ¼ 2.3x10
À5
). None of the SNPs (rs113640578, rs79324425, rs11666929, rs28384475, rs3810287, rs78353057, and rs201147694) are predicted to change the KLK6 amino acid sequence. Bioinformatic characterization of the seven KLK6 SNPs associated with PCa aggressiveness suggested they may have regulatory functions ( Figure 1B ): rs11666929 is in a RAD21 protein binding site, while three SNPs are in DNAse-sensitive regions (rs11666929, ARTICLE rs28384475, rs3810287) and four were at potential histone modification sites (rs28384475, rs201147694, rs3810287, rs11666929). None of the variants (rs113640578, rs79324425, rs11666929, rs28384475, and rs3810287) was associated with serum KLK3 (PSA) levels (measured by ELISA) or age at diagnosis, but all were associated with GS in the pooled Swiss-Toronto data set (P ¼ .01, t test, data not shown). These five variants in the KLK6 region remained statistically significant after adjustment for serum PSA levels in the Swiss (P ¼ 9. was 79.4% and 62.6% in the Swiss and Toronto cohorts, respectively; adding rs79015965 (KLK2/KLK3 region) and rs113640578 (KLK6 region) increased the AUC by 3.6 of 4.9 points in both cohorts, respectively (data not shown). As all KLK6 SNPs were in strong LD, we used one SNP only to build the AUC (rs113640578).
As we previously showed that KLK6 DNA methylation distinguishes organ confined from locally invasive PCa (21), we assessed the association of these KLK6 SNPs with the methylation level of KLK6 in the Toronto cohort at the tissue level. Based on covariance analysis of GS, we found a statistically significant interaction between the SNP rs113640578 in KLK6 and the PMR differential KLK6 score PMR diff , used to determine GS (P ¼ .05, Wald test, data not shown).
These methylation differences led us to hypothesize that the noncoding germline SNPs in KLK6 might be associated with unique somatic mutation profiles in tumors. We tested this in the cohort of 186 patients with whole-genome sequencing of tumor/normal pairs and transcriptome and methylome analysis of the tumors from the ICGC (26) . In this cohort, four SNPs were in complete linkage disequilibrium (group 1, rs79324425, rs11666929, rs28384475, rs3810287). We tested a panel of 22 somatic events identified as recurrent in localized PCa: six coding single-nuceotide variants (SNVs), eight copy number alteration (CNA)s, four inversions, and four translocations (Figure 2A ; Supplementary Table 3, available online) (26) . Tumors arising in patients harboring these risk SNPs were less likely to harbor the Table 3 . Association of PCa aggressiveness with KLK6 SNPs in the Swiss, Toronto, and PLCO data sets Table 4 , available online). We compared biochemical relapse rates between patients with and without each group of SNPs. The set of group 1 genotypes (rs79324425, rs11666929, rs28384475, and rs3810287) was strongly associated with patient biochemical relapse-free survival even after adjustment for GS, serum PSA, and tumor size (hazard ratio [HR] ¼ 3.15, 95% CI ¼ 1.57 to 6.34, P ¼ .001, Waldtest) ( Figure 2B ). Similarly Kaplan-Meier plots showed that patients harboring the rs268890 SNP (found in the PLCO cohort) had a worse biochemical relapse-free survival than patients with the reference allele (HR ¼ 2.01, 95% CI ¼ 1.10 to 3.66, P ¼ .02, data not shown). To determine if these germline SNPs could be used in combination with existing molecular markers, we tested the effect of including the proportion of genome with a copynumber alteration (PGA) in our survival model. PGA reflects genomic instability and is a robust prognostic marker for localized disease (30) Figure 4 and Supplementary Tables 5 and 6 , available online), demonstrating that the germline genotype is informative even in the context of molecular prognostic information derived from the primary tumor.
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Discussion
This study found novel evidence that germline mutations in the KLK6 gene are strongly associated with an increased risk of aggressive PCa using a stringent definition (GS ! 8). The SNPs found from our discovery cohorts (Swiss arm of the ERSPC and Toronto) are in very strong linkage disequilibrium and located on the same haplotype block; they reside within transcription factor binding sites. One germline SNP showed a clear association with KLK6 methylation levels in determining the GS in radical prostatectomy specimens. Sukumar et al. mined KLK SNVs across Ensembl and Exome Variant Server, with exomesequencing data from 6503 individuals (30) . They identified two common missense SNVs within KLK6 with potential damaging functions (rs77760094 and rs61469141) and three SNVs located in transcription factor binding sites (rs1722537, rs13345726, rs11666929). Interestingly, the two first SNPs are within 1 Kb from the SNPs we found to be associated with PCa aggressiveness in our cohorts, and the SNP rs11666929 was present in our data and strongly associated with PCa aggressiveness as well.
The validation study on a cohort from the PLCO study confirmed the findings from the discovery phase and revealed another important KLK6 haplotype with two SNPs at the same locus to be associated with aggressive PCa. The overall test of haplotype association was highly statistically significant in each of the three data sets (Swiss, Toronto, and PLCO) and when combining them together. We then asked if these germline noncoding KLK6 SNPs could be used in a clinically challenging setting, namely intermediaterisk disease, to predict PCa aggressiveness and outcomes. We exploited a data set of 130 tumors with whole-genome sequencing from the ICGC with follow-up data. KLK6 SNPs predicted PSA failure (biochemical relapse) in these patients even after adjustment for GS or classical clinical parameters. These noncoding SNPs in KLK6 were additive with existing molecular tools like a validated molecular diagnostic from primary tumors, PGA (31) . So far, few germline genetic variants have been shown to be associated with aggressive PCa and to provide prognostic information regarding PCa-specific survival (32) . These include SNPs in BRCA2, IGF signaling, and estradiol metabolism-related pathways, as well as HOXB13 (33) (34) (35) (36) (37) .
The exact role of KLK6 in tumor progression remains elusive. It encodes for an enzyme with trypsin-like properties and can degrade components of the extracellular matrix. KLK6 is implicated in processes such as epithelial-to-mesenchymal transition, angiogenesis, and invasion, in keeping with biological functions required by tumors to display an aggressive phenotype (38) .
With seven exons and six introns, KLK6 spans approximately 11.0 kb (NCBI ReferenceSequence: NG_011825.1), mapping between KLK5 and KLK7 (24) . Our knowledge about the role of KLK6 in PCa is also limited. Even the regulation of KLK6 by androgens is controversial (39) . Additional studies of the regulation and function of the KLK6 locus are warranted to explain its prognostic value.
Our study is not without limitations. The SNPs were found by imputation, and further validation by genotyping or sequencing additional cohorts could be performed. However, in other large-scale studies, the most statistically significant associations were also observed with imputed variants and we were able to confirm the value of the imputed KLK6 genotypes by next-generation sequencing in our cohort from the ICGC (2). It is possible that these different KLK6 SNPs associated with aggressive PCa might be tagging for rare variants with major effects in the same region. These might be unraveled by future deep sequencing of the KLK6 locus to find the causal variant(s) (40) .
In summary, we have found strong preliminary evidence that germline mutations in the KLK6 gene are associated with an increase in the risk of aggressive PCa. Our findings may have clinical implications. Ultimately incorporating these SNPS or future rare variants in the KLK6 region into clinical practice may directly impact and improve PCa screening and early diagnosis strategies. Moving from "indiscriminate" to "personalized" screening should be encouraged, including, for instance, BRCA2 and KLK6 variants, which might be integrated in future approaches.
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